HPVC2019-058 Pharmaceutical Products and IV Fluids

Current Contract

Contract Start Date: 30 Jan 2020
Contract End Date: 29 Jan 2022
Option Periods: 2 x 2 Year

Description

Contract for the provision of a range of pharmaceutical products and intravenous fluids to Victorian Public Health Services.

Additional Information

Update 1: 16 February 2021

Upcoming Supplementary Tender

Market Release Date 01-03-2021
Provisional Contract Commencement Date: 10-06-2021

Title: HPVITS2019-058.003 – Pharmaceutical Products and IV Fluids Supplementary 003

Scope:

Subcategory number	Subcategory name
517.01	Arsenic trioxide 10mg/10mL injection, ampoule/vial,10mL
83001.01	Bevacizumab 100mg/4mL injection, ampoule/vial, 4mL
83001.02	Bevacizumab 400mg/16mL injection, ampoule/vial, 16mL
518.01	Bortezomib injection, ampoule/vial
519.01	Cabazitaxel 60mg injection, ampoule/vial
527.01	Carmustine 100mg injection, ampoule/vial
520.01	Daptomycin 350mg injection, ampoule/vial
520.02	Daptomycin 500mg injection, ampoule/vial
521.01	Deferasirox 90mg tablet/capsule 30
521.02	Deferasirox 180mg tablet/capsule 30
521.03	Deferasirox 360mg tablet/capsule 30
522.01	Desflurane 1mL/1mL or 1g/1g Inhalation solution, bottle 250mL
197.03	Furosemide (Frusemide) 20mg/2mL injection, ampoule/vial, 2mL
523.01	Imatinib 100mg tablet/capsule 30 (GIST indication)
523.02	Imatinib 100mg tablet/capsule 30 (non-GIST indication)
523.03	Imatinib 400mg tablet/capsule 60 (GIST indication)
523.04	Imatinib 400mg tablet/capsule 60 (non-GIST indication)
524.01	Methylprednisolone (sodium succinate) 500mg injection, ampoule/vial
524.02	Methylprednisolone (sodium succinate) 1g injection, ampoule/vial
325.02	Moxifloxacin 400mg tablet/capsule 5
525.01	Oseltamivir 30mg capsule 10
525.02	Oseltamivir 45mg capsule 10
525.03	Oseltamivir 75mg capsule 10
526.01	Sodium nitroprusside 50mg/2mL injection, ampoule/vial, 2mL
499.04	Vancomycin 500mg injection, ampoule/vial

All enquiries regarding this supplementary tender prior to the market release date should be directed to r.luong@healthsharevic.org.au or (03)99473933 . Once the tender has been released, please direct all correspondence through the HSV Procurement Portal.

Update 2: 16 February 2021

Upcoming Procurement Activity

Market Engagement Date: 22 February 2021 – 26 February 2021

Announcement of outcome to suppliers: 12 March 2021

Announcement of outcome to health services: 23 March 2021

Contract Commencement Date: 1 April 2021

HSV will be engaging directly with all suppliers with current ARTG registration for Rituximab intravenous.

Scope:

81001.02 RITUXIMAB 100 MG/10 ML INJECTION, AMPOULE/VIAL 10 ML

81001.03 RITUXIMAB 500 MG/50 ML INJECTION, AMPOULE/VIAL 50 ML.

Please note all queries and correspondence should be directed to pharmaceuticals@healthsharevic.org.au.

Useful information:

1. To subscribe and receive contract update notifications, favourite this contract cabinet.
2. Review your account settings to ensure the notification frequency selected is adequate.
3. Information for Prospective Suppliers can be found on our website: https://www.hpv.org.au/tenders-and-contracts/information-for-prospective-suppliers/